Lantheus (NASDAQ:LNTH) Issues FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $6.60-6.70 for the period, compared to the consensus EPS estimate of $7.07. The company issued revenue guidance of $1.50-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.600-6.700 EPS.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. B. Riley increased their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a buy rating in a report on Thursday, July 25th. StockNews.com cut shares of Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Mizuho increased their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research note on Friday, May 3rd. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a market outperform rating for the company in a research note on Thursday. Finally, Truist Financial cut their price target on shares of Lantheus from $141.00 to $135.00 and set a buy rating for the company in a research note on Thursday. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of Moderate Buy and a consensus price target of $119.00.

Lantheus Price Performance

LNTH stock opened at $97.59 on Friday. The company has a quick ratio of 4.55, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus has a 12 month low of $50.20 and a 12 month high of $126.89. The firm has a market cap of $6.78 billion, a P/E ratio of 14.90 and a beta of 0.51. The company’s 50-day moving average price is $92.18 and its two-hundred day moving average price is $73.12.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same period in the prior year, the business earned $1.40 earnings per share. Lantheus’s quarterly revenue was up 22.5% compared to the same quarter last year. On average, analysts anticipate that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Heinz Christoph Maeusli sold 18,373 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares in the company, valued at approximately $6,408,285.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now owns 23,340 shares in the company, valued at $1,848,294.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,799 shares of company stock worth $3,769,262. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.